| May 30 |
Candel gains FDA orphan status for brain tumor candidate
|
| May 30 |
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
|
| May 28 |
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
|
| May 24 |
Candel Reports Upbeat Data From Lung Cancer Study
|
| May 24 |
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
|
| May 23 |
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
|
| May 22 |
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
|
| May 20 |
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
|
